Hepatology (Baltimore, Md.)
NRF2-COX2-PGE2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.
Shuhei Yamamoto, Takahiro Kodama, Akifumi Kuwano, Kazuki Maesaka, Tomomi Yoshida-Hashidate, Hideo Shindou, Haruhiko Takeda, Kumiko Shirai, Yuta Myojin, Kazuhiro Murai, Yuki Makino, Yuki Tahata, Yoshinobu Saito, Atsushi Hosui, Yasutoshi Nozaki
Published: 202610.1097/HEP.0000000000001677
Abstract
BACKGROUND AIMS: Atezolizumab plus bevacizumab (Atez/Bev) is the first-line immunotherapy for advanced hepatocellular carcinoma (HCC), yet many patients show primary or acquired resistance. We aimed to identify tumor-intrinsic mechanisms driving immu…
Preview only. Read the full abstract at the source